Lilly Trulicity News Today

BioPharma

Some patients with type 2 diabetes say they are having more difficulty getting reimbursed for drugs like Ozempic as U.S. insurers implement restrictions designed to deter doctors from prescribing the...

Some patients with type 2 diabetes say they are having more difficulty getting reimbursed for drugs like Ozempic as U.S. insurers implement restrictions designed to deter...

There is growing concern among some type 2 diabetes patients over challenges in obtaining reimbursement for medications like Novo Nordisk A/S's (NYSE: NVO) Ozempic amid stricter health plan 

Some patients with type 2 diabetes say they are having more difficulty getting reimbursed for drugs like Ozempic as U.S. insurers implement restrictions designed to deter doctors from prescribing... -December 12, 2023 at 11:43 am EST - MarketScreener

Like rival Novo Nordisk, Eli Lilly has also been struggling to meet high demand for its diabetes drugs including Trulicity, which treats type 2 diabetes in people older than 10. Novo's diabetes drug Ozempic was in short supply for months in the U.S., partly driven by prescriptions to non-diabetic patients seeking to lose weight.

Investors could be forgiven if talk of a potential suicide risk associated with a new class of diabetes and weight loss drugs led to skittishness last week.

Out of necessity, the industry will have to make significant cuts to its R&D operations. Research sites will be cut back or eliminated, therapeutic areas will be dropped and jobs will be lost.

Weight-loss drugs could be a $60 billion market in 10 years. These companies stand to benefit.

The private equity giant is testing a program from startup Twin Health with workers across 14 of its portfolio companies. The app is designed to help diabetics rely less on expensive drugs to lose weight and control their blood sugar